Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10039136HBVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS30073496HIVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS30073497HIVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS20011278HPVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS20029983HPVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS20029984HPVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS20029985HPVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS20029986HPVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS20029987HPVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS20064469HPVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TCGA Plot Options
Drug Information
GeneHTR2C
DrugBank IDDB00714
Drug NameApomorphine
Target IDBE0000533
UniProt IDP28335
Regulation Typeagonist
PubMed IDs18691132; 15037665
CitationsKvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67.@@LeWitt PA: Subcutaneously administered apomorphine: pharmacokinetics and metabolism. Neurology. 2004 Mar 23;62(6 Suppl 4):S8-11. doi: 10.1212/wnl.62.6_suppl_4.s8.
GroupsApproved; Investigational
Direct ClassificationAporphines
SMILES[H][C@]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23
Pathways
PharmGKBPA164781163
ChEMBLCHEMBL53